Drug intelligence / Profile preview

paclitaxel + cisplatin + cadonilimab

Development stage: Unknown
Lead developer: Akeso
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of paclitaxel (a taxane chemotherapy agent), cisplatin (a platinum-based chemotherapy agent), and cadonilimab (a bispecific antibody targeting both PD-1 and CTLA-4 immune checkpoints). This regimen has been studied primarily for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and head and neck squamous cell carcinoma (HNSCC), particularly in patients who have failed previous anti-PD-1 therapy.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on paclitaxel + cisplatin + cadonilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + cisplatin + cadonilimab.

Explore the full profile